Last reviewed · How we verify
Glimepiride Rescue Medication
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glimepiride Rescue Medication |
|---|---|
| Also known as | AMARYL |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Sulfonylurea |
| Target | Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose levels in patients with type 2 diabetes by increasing endogenous insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Dizziness
- Headache
Key clinical trials
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
- Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients (PHASE4)
- Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) (PHASE3)
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) (PHASE3)
- Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) (PHASE3)
- INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes (PHASE4)
- Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glimepiride Rescue Medication CI brief — competitive landscape report
- Glimepiride Rescue Medication updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI